source
- FDA approves GSK hepatitis B drug; EQT to acquire Qiagen for $10.8 billionThe U.S. Food and Drug Administration has granted approval to GlaxoSmithKline's new hepatitis B therapy, marking a regulatory milestone for the company. Private-equity firm EQT announced a definit…
- FDA launches Neuroscience Advancement and Innovation Nexus to boost brain disorder drug developmentThe U.S. Food and Drug Administration announced a new program called the Neuroscience Advancement and Innovation Nexus (NAIN) aimed at accelerating the development of medical products for brain and…